Allergan (NYSE:AGN)‘s stock had its “buy” rating reaffirmed by analysts at Wells Fargo & Co in a report released on Saturday.

Other analysts have also issued reports about the stock. Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $189.00 price target for the company in a research report on Monday, July 2nd. Credit Suisse Group set a $213.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Tuesday, June 12th. Bank of America increased their price target on shares of Allergan from $209.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday, June 12th. Sanford C. Bernstein set a $232.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Friday, June 8th. Finally, Mizuho raised shares of Allergan from a “neutral” rating to a “buy” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the stock. Allergan has a consensus rating of “Buy” and an average target price of $210.10.

Shares of Allergan stock opened at $188.22 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.85 and a debt-to-equity ratio of 0.34. Allergan has a 1 year low of $142.81 and a 1 year high of $227.54. The stock has a market cap of $64.61 billion, a price-to-earnings ratio of 11.51, a price-to-earnings-growth ratio of 1.46 and a beta of 1.21.

Allergan (NYSE:AGN) last issued its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $4.02 EPS. equities research analysts forecast that Allergan will post 16.29 earnings per share for the current fiscal year.

In related news, Director Joseph H. Boccuzi acquired 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was bought at an average cost of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. Company insiders own 0.36% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans raised its position in Allergan by 3.1% during the 1st quarter. Thrivent Financial for Lutherans now owns 13,879 shares of the company’s stock worth $2,336,000 after buying an additional 412 shares during the last quarter. Riverhead Capital Management LLC raised its position in Allergan by 133.0% during the 1st quarter. Riverhead Capital Management LLC now owns 12,036 shares of the company’s stock worth $2,025,000 after buying an additional 6,871 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in Allergan by 10.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 21,555 shares of the company’s stock worth $3,627,000 after buying an additional 2,030 shares during the last quarter. Haverford Trust Co. purchased a new position in Allergan during the 1st quarter worth approximately $304,000. Finally, Guyasuta Investment Advisors Inc. raised its position in Allergan by 1.5% during the 1st quarter. Guyasuta Investment Advisors Inc. now owns 69,361 shares of the company’s stock worth $11,673,000 after buying an additional 1,005 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: Asset Allocation

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.